To understand the role of Cu and Zn in human blood both in controls as well as in cardiovascular (CVD) patients, whole blood samples of 181 CVD and 185 controls between the ages of 20–66 years were investigated. Instrumental neutron activation analysis (INAA) and flame atomic absorption spectrophotometric techniques were successfully employed to quantification Cu and Zn levels. The mean blood-Cu levels (1.50 mg L−1) were found as enhanced whereas Zn levels (5.88 mg L −1) were reduced in cardiovascular patients group as compared to 0.90 and 6.70 mg L−1 for Cu and Zn respectively in controls. Cu/Zn ratios for CVD patients are also higher than in control subjects. Negative correlation exists between Cu and Zn levels in both controls and patient groups. However, when the CVD patients were checked for their systolic and diastolic pressure it was found that copper concentrations in these patients was significantly increased (p < 0.001) with the rise of blood systolic pressure so a positive correlation was observed between copper and systolic pressure. Zn on the other hand has an inverse relation with systolic as well as diastolic pressure (p < 0.001). Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, and triglyceride (TG) in blood samples have also been determined and their probable role in the CVD complication has been observed. A positive correlation of blood-Cu with TC, TG, and LDL-C indicates that rise in blood-Cu levels may initiate the development of CVD. An increase in Cu/Zn ratio can instigate the cardiovascular risk factor. The findings from this study can definitely update our knowledge of the role of Cu and Zn in the development of CVD risk in humans.
